Top

European Journal of Nutrition

Published in:

01-03-2013 | Review

Vitamin D metabolism, functions and needs: from science to health claims

Authors: S. Battault, S. J. Whiting, S. L. Peltier, S. Sadrin, G. Gerber, J. M. Maixent

Published in: European Journal of Nutrition | Issue 2/2013

Abstract

Background

Vitamin D is a nutrient long considered as essential for skeletal health but is now attracting interest from medical and nutritional communities as knowledge emerges of its biological function and its association with decreased risk of many chronic diseases.

Results

A question emerges: How much more vitamin D do we need for these new functions of vitamin D? This review discusses vitamin D physiology and hypovitaminosis D and presents two vitamin D dietary policies: that according to regulatory authorities and that of nutrition scientists. Scientific evidence suggests that 25(OH)D serum levels should be over 75 nmol/L; otherwise, there is no beneficial effect of vitamin D on long-latency diseases. Current regulatory authority recommendations are insufficient to reach this level of adequacy. Observational and some prospective data show that vitamin D has a role in the prevention of cancer as well as immunity, diabetes and cardiovascular and muscle disorders, which supports the actions of 1α,25(OH)2D at cellular and molecular levels. The recent assessments done by the European Food Safety Authority should lead to new health claims.

Conclusions

Vitamin D, through food fortification and supplementation, is a promising new health strategy and thus provides opportunities for food industry and nutrition researchers to work together towards determining how to achieve this potential health benefit.

Norman AW, Bouillon R (2010) Vitamin D nutritional policy needs a vision for the future. Exp Biol Med 235(9):1034–1045. doi:10.1258/ebm.2010.010014 CrossRef

Holick MF, Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87(4):1080S–1086S

Heaney RP (2008) Vitamin D in health and disease. Clin J Am Soc Nephrol 3(5):1535–1541. doi:10.2215/CJN.01160308 CrossRef

Holick MF, MacLaughlin JA, Doppelt SH (1981) Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science 211(4482):590–593CrossRef

Linos E, Keiser E, Kanzler M, Sainani K, Lee W, Vittinghoff E, Chren M-M, Tang J (2011) Sun protective behaviors and vitamin D levels in the US population: NHANES 2003–2006. Cancer Causes Control 1–8. doi:10.1007/s10552-011-9862-0

Hall LM, Kimlin MG, Aronov PA, Hammock BD, Slusser JR, Woodhouse LR, Stephensen CB (2010) Vitamin D intake needed to maintain target serum 25-hydroxyvitamin D concentrations in participants with low sun exposure and dark skin pigmentation is substantially higher than current recommendations. J Nutr. doi:10.3945/jn.109.115253

Houghton LA, Vieth R (2006) The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 84(4):694–697

Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, Chope G, Hyppönen E, Berry J, Vieth R, Lanham-New S (2012) Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. doi:10.3945/ajcn.111.031070

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. doi:10.1210/jc.2011-0385

10.

Whiting SJ, Calvo MS, Stephensen CB (2008) Current understanding of vitamin D, metabolism, nutritional status, and role in disease prevention. In: Coulston AM, Boushey C (eds) Nutrition in the prevention and treatment of disease. Academic Press, San Diego, pp 807–832

11.

Schuster I (2011) Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta Proteins Proteomics 1814(1):186–199. doi:10.1016/j.bbapap.2010.06.022 CrossRef

12.

Whitfield GK, Hsieh J-C, Jurutka PW, Selznick SH, Haussler CA, Macdonald PN, Haussler MR (1995) Genomic actions of 1, 25-dihydroxyvitamin D3. J Nutr 125(6 Suppl):1690S–1694S

13.

Holick MF (2007) Vitamin D deficiency. New Engl J Med 357(3):266–281. doi:10.1056/NEJMra070553 CrossRef

14.

Sturm RA (1998) Human pigmentation genes and their response to solar UV radiation. Mutat Res Fundam Mol Mech Mutagen 422(1):69–76. doi:10.1016/s0027-5107(98)00176-6 CrossRef

15.

Gombart AF (2009) The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Futur Microbiol 4(9):1151–1165. doi:10.2217/fmb.09.87 CrossRef

16.

Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, Handunnetthi L, Handel AE, Disanto G, Orton S-M, Watson CT, Morahan JM, Giovannoni G, Ponting CP, Ebers GC, Knight JC (2010) A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 20(10):1352–1360. doi:10.1101/gr.107920.110 CrossRef

17.

Norman AW (2008) From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88(2):491S–499S

18.

Mizwicki MT, Norman AW (2009) The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. Sci Signal 2(75):re4. doi:10.1126/scisignal.275re4

19.

Norman AW, Mizwicki MT, Norman DPG (2004) Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3(1):27–41CrossRef

20.

Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW (2004) The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1α,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 18(11):2660–2671. doi:10.1210/me.2004-0116 CrossRef

21.

Ricardo LB (2011) VDR activation of intracellular signaling pathways in skeletal muscle. Mol Cell Endocrinol 347(1–2):11–16. doi:10.1016/j.mce.2011.05.021

22.

Norman AW (1995) Transcaltachia (the rapid hormonal stimulation of intestinal calcium transport): a component of adaptation to calcium needs and calcium availability. Am Zool 35(6):483–489. doi:10.1093/icb/35.6.483

23.

Fleet JC, Schoch RD (2011) Molecular mechanisms for regulation of intestinal calcium and phosphate absorption by vitamin D. In: David F, Pike JW, John SA (eds) Vitamin D, 3rd edn. Academic Press, San Diego, pp 349–362. doi:10.1016/b978-0-12-381978-9.10019-8 CrossRef

24.

Doyle ME, Jan de Beur SM (2008) The skeleton: endocrine regulator of phosphate homeostasis. Curr Osteoporos Rep 6(4):134–141CrossRef

25.

Bergwitz C, Juppner H (2010) Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 61:91–104. doi:10.1146/annurev.med.051308.111339 CrossRef

26.

Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12(1):17–25. doi:10.1016/j.molmed.2005.11.007 CrossRef

27.

Anderson PH, Atkins GJ (2008) The skeleton as an intracrine organ for vitamin D metabolism. Mol Aspects Med 29(6):397–406. doi:10.1016/j.mam.2008.05.003 CrossRef

28.

Ingraham BA, Bragdon B, Nohe A (2008) Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 24(1):139–149. doi:10.1185/030079908X253519

29.

Garland CF, Grant WB, Mohr SB, Gorham ED, Garland FC (2007) What is the dose-response relationship between vitamin D and cancer risk? Nutr Rev 65:S91–S95. doi:10.1111/j.1753-4887.2007.tb00349.x CrossRef

30.

Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7(9):684–700. doi:10.1038/nrc2196 CrossRef

31.

Schwandner OS, Bruch HPB, Broll RB (2002) p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance? Int J Colorectal Dis 17(1):11–19. doi:10.1007/s003840100333 CrossRef

32.

Hager G, Formanek M, Gedlicka C, Thurnher D, Knerer B, Kornfehl J (2001) 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 121(1):103–109CrossRef

33.

Pálmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Muñoz A (2001) Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J Cell Biol 154(2):369–388. doi:10.1083/jcb.200102028 CrossRef

34.

Shawi M, Autexier C (2008) Telomerase, senescence and ageing. Mech Ageing Dev 129(1–2):3–10. doi:10.1016/j.mad.2007.11.007 CrossRef

35.

Zakian VA (2012) Telomeres: the beginnings and ends of eukaryotic chromosomes. Exp Cell Res 318(12):1456–1460. doi:10.1016/j.yexcr.2012.02.015 CrossRef

36.

Campisi J, S-h Kim, Lim C-S, Rubio M (2001) Cellular senescence, cancer and aging: the telomere connection. Exp Gerontol 36(10):1619–1637. doi:10.1016/s0531-5565(01)00160-7 CrossRef

37.

Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1α,25-Dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res 87(3):214–220. doi:10.1161/01.res.87.3.214 CrossRef

38.

Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24(50):7443–7454CrossRef

39.

Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C (2010) Vitamin D: modulator of the immune system. Curr Opin Pharm 10(4):482–496. doi:10.1016/j.coph.2010.04.001 CrossRef

40.

Wang T–T, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JH, Mader S, White JH (2004) Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173(5):2909–2912

41.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311(5768):1770–1773. doi:10.1126/science.1123933 CrossRef

42.

Mora JR, Iwata M, von Andrian UH (2008) Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 8(9):685–698. doi:10.1038/nri2378 CrossRef

43.

Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stähelin HB, Dick W (2001) In situ detection of 1, 25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem J 33(1):19–24. doi:10.1023/a:1017535728844 CrossRef

44.

Lisa C (2008) Vitamin D and skeletal muscle tissue and function. Mol Aspects Med 29(6):407–414. doi:10.1016/j.mam.2008.07.002 CrossRef

45.

Vazquez G, De Boland AR, Boland RL (1998) 1α, 25-Dihydroxy-vitamin-D3-induced store-operated Ca2+ influx in skeletal muscle cells: modulation by phospholipase C, protein kinase C, and tyrosine kinases. J Biol Chem 273(51):33954–33960CrossRef

46.

Vazquez G, de Boland AR, Boland R (1997) Stimulation of Ca2+ release-activated Ca2+ channels as a potential mechanism involved in non-genomic 1, 25(OH)2-vitamin D3-induced Ca2+ entry in skeletal muscle cells. Biochem Biophys Res Commun 239(2):562–565. doi:10.1006/bbrc.1997.7501 CrossRef

47.

Boland R, De Boland AR, Buitrago C, Morelli S, Santillán G, Vazquez G, Capiati D, Baldi C (2002) Non-genomic stimulation of tyrosine phosphorylation cascades by 1, 25(OH)2D3 by VDR-dependent and -independent mechanisms in muscle cells. Steroids 67(6):477–482. doi:10.1016/s0039-128x(01)00182-9 CrossRef

48.

De Boland AR, Boland RL (1994) Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal 6(7):717–724CrossRef

49.

Rostand SG, Drueke TB (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56(2):383–392CrossRef

50.

Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P (2002) 1, 25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110(2):229–238

51.

Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J (2004) Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89–90:387–392. doi:10.1016/j.jsbmb.2004.03.004 CrossRef

52.

Zhao G, Simpson RU (2010) Membrane localization, Caveolin-3 association and rapid actions of vitamin D receptor in cardiac myocytes. Steroids 75(8–9):555–559. doi:10.1016/j.steroids.2009.12.001 CrossRef

53.

Zhao G, Simpson RU (2010) Interaction between vitamin D receptor with caveolin-3 and regulation by 1, 25-dihydroxyvitamin D3 in adult rat cardiomyocytes. J Steroid Biochem Mol Biol 121(1–2):159–163. doi:10.1016/j.jsbmb.2010.03.055 CrossRef

54.

Pittas AG, Lau J, Hu FB, Dawson-Hughes B (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92(6):2017–2029. doi:10.1210/jc.2007-0298 CrossRef

55.

Maestro B, Molero S, Bajo S, Dávila N, Calle C (2002) Transcriptional activation of the human insulin receptor gene by 1, 25-dihydroxyvitamin D3. Cell Biochem Funct 20(3):227–232. doi:10.1002/cbf.951 CrossRef

56.

Pittas AG, Dawson-Hughes B (2011) The role of vitamin D in type 2 diabetes and hypertension. In: David F, Pike JW, John SA (eds) vitamin D, 3rd edn. Academic Press, San Diego, pp 1907–1930. doi:10.1016/b978-0-12-381978-9.10098-8 CrossRef

57.

Grundy SM (2008) A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor. Eur Heart J Supp 10(suppl B):B16–B23. doi:10.1093/eurheartj/sum044

58.

Ebert R, Schütze N, Adamski J, Jakob F (2006) Vitamin D signaling is modulated on multiple levels in health and disease. Mol Cell Endocrinol 248(1–2):149–159. doi:10.1016/j.mce.2005.11.039 CrossRef

59.

Lips P (2006) Vitamin D physiology. ProgBiophys Mol Biol 92(1):4–8. doi:10.1016/j.pbiomolbio.2006.02.016 CrossRef

60.

Hughes MR, Malloy PJ, Kieback DG, Kesterson RA, Pike JW, Feldman D, O’Malley BW (1988) Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 242(4886):1702–1705CrossRef

61.

Sultan A-K, Vitale P (2003) Vitamin D-dependent rickets type II with alopecia: two case reports and review of the literature. Int J Dermatol 42(9):682–685. doi:10.1046/j.1365-4362.2003.01816.x CrossRef

62.

Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DE, Atkinson SA, Josse RG, Feldman S, Kline GA, Rosen C (2010) Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 182(12):E610–E618. doi:10.1503/cmaj.080663

63.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2012) Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. doi:10.1210/jc.2011-2601

64.

Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135(2):317–322

65.

Rosen CJ (2011) Vitamin D insufficiency. New Engl J Med 364(3):248–254. doi:10.1056/NEJMcp1009570 CrossRef

66.

Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, Proksch N, Pastor F, Netter C, Streichert T, Puschel K, Amling M (2010) Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 25(2):305–312. doi:10.1359/jbmr.090728 CrossRef

67.

Heaney RP (2003) Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr 78(5):912–919

68.

Hathcock JN, Shao A, Vieth R, Heaney R (2007) Risk assessment for vitamin D. Am J Clin Nutr 85(1):6–18

69.

Institute of Medicine (2010) Dietary reference intakes for calcium and vitamin D. National Academy of Sciences. http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Report%20Brief.pdf

70.

EFSA Panel on Dietetic Products, Nutrition and Allergies Panel Members (2006) Tolerable upper intake levels for vitamins and minerals. http://www.efsa.europa.eu/en/ndatopics/docs/ndatolerableuil.pdf

71.

Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD (2010) Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). CMAJ 182(12):1315–1319. doi:10.1503/cmaj.091062

72.

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84(1):18–28

73.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad HM, Weaver, The Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. http://www.endo-society.org/guidelines/final/upload/FINAL-Standalone-Vitamin-D-Guideline.pdf

74.

Vieth R (2007) Vitamin D toxicity, policy, and science. J Bone Miner Res 22(S2):V64–V68. doi:10.1359/jbmr.07s221 CrossRef

75.

Jones G (2008) Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88(2):582S–586S

76.

Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF (1998) Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int 8(3):222–230. doi:10.1007/s001980050058 CrossRef

77.

Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest 116(8):2062–2072. doi:10.1172/JCI29449 CrossRef

78.

Al-Aqeel A, Ozand P, Sobki S, Sewairi W, Marx S (1993) The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII). Clin Endocrinol 39(2):229–237. doi:10.1111/j.1365-2265.1993.tb01779.x CrossRef

79.

Takeda E, Yokota I, Kawakami I, Hashimoto T, Kuroda Y, Arase S (1989) Two siblings with vitamin-D-dependent rickets type II: no recurrence of rickets for 14 years after cessation of therapy. Eur J Pediatr 149(1):54–57. doi:10.1007/bf02024336 CrossRef

80.

Chen H, Hewison M, Hu B, Adams JS (2003) Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: a cause of vitamin D resistance. Proc Natl Acad Sci 100(10):6109–6114. doi:10.1073/pnas.1031395100 CrossRef

81.

Canadian Cancer Society (2011). http://www.cancer.ca/Saskatchewan/Prevention/Vitamin%20D.aspx?sc_lang=en

82.

Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (2001) Apports nutritionnels conseillés en vitamine D pour la population française. http://www.anses.fr/Documents/ANC-Ft-TableauVitD.pdf

83.

Department of Health (2009) Vitamin D an essential nutrient for all… but who is at risk of vitamin D deficiency? http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_111302.pdf

84.

Food and Drug Administration (2009) Guidance for industry: a food labeling guide; appendix C: health claims. http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodLabelingNutrition/FoodLabelingGuide/ucm064919.htm

85.

Food Inspection Agency (2011) Guide to food labelling and advertising; Chapter 8 health claims. http://www.inspection.gc.ca/francais/fssa/labeti/guide/ch8f.shtml

86.

EFSA Panel on Dietetic Products, Nutrition and Allergies Panel Members (2009) Scientific opinion on the substantiation of health claims related to vitamin D and maintenance of bone and teeth (ID 150, 151, 158), absorption and utilisation of calcium and phosphorus and maintenance of normal blood calcium concentrations (ID 152, 157), cell division (ID 153), and thyroid function (ID 156) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 7(9):1227. doi:10.2903/j.efsa.2009.1227

87.

EFSA Panel on Dietetic Products, Nutrition and Allergies Panel Members (2009) Scientific opinion on the substantiation of health claims related to calcium and vitamin D and maintenance of bone (ID 350) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 7(9):1272. doi:10.2903/j.efsa.2009.1272

88.

EFSA Panel on Dietetic Products, Nutrition and Allergies Panel Members (2009) Scientific Opinion on health claims already evaluated (ID 215, 568, 674, 712, 1398, 1633, 1974, 4191, 4192, 4193, 4236, 4335, 4698, 4704) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 9 (6):2203. doi:10.2903/j.efsa.2011.2203

89.

EFSA Panel on Dietetic Products, Nutrition and Allergies Panel Members (2010) Scientific opinion in relation to the authorisation procedure for health claims on calcium and vitamin D and the reduction of the risk of osteoporotic fractures by reducing bone loss pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J 8(5):1609

90.

EFSA Panel on Dietetic Products, Nutrition and Allergies Panel Members (2010) Scientific opinion on the substantiation of health claims related to vitamin D and normal function of the immune system and inflammatory response (ID 154, 159), maintenance of normal muscle function (ID 155) and maintenance of normal cardiovascular function (ID 159) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 8(2):1468. doi:10.2903/j.efsa.2010.1468

Title: Vitamin D metabolism, functions and needs: from science to health claims
Authors: S. Battault
S. J. Whiting
S. L. Peltier
S. Sadrin
G. Gerber
J. M. Maixent
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: European Journal of Nutrition / Issue 2/2013
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-012-0430-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Effects of pre-exercise feeding on serum hormone concentrations and biomarkers of myostatin and ubiquitin proteasome pathway activity

Breast milk fatty acid composition differs between overweight and normal weight women: the STEPS Study

Chlorella pyrenoidosa ameliorated L-NAME-induced hypertension and cardiorenal remodeling in rats

Maternal high-fat diet is associated with altered pancreatic remodelling in mice offspring

Evidence of altered biochemical composition in the hearts of adult intrauterine growth-restricted rats

Combined arginine and glutamine decrease release of de novo synthesized leukotrienes and expression of proinflammatory cytokines in activated human intestinal mast cells

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage